On July 23-24 an FDA advisory committee (PCAC) recommended six of seven peptides for the 503A compounding list. It was the most-covered event in this market in years. I publish PeptideScouter's price index, so I checked whether it did anything to prices.



Method: every listing compared against itself, the week of July 9-15 vs the week of August 5-11, with the vote in between. A listing counts only if it was in stock and priced in both weeks.



\- The five measurable recommended peptides (BPC-157, KPV, MOTS-c, Semax, Epitalon): 133 matched listings from 22 vendors, 22.6% changed price, median change zero.

\- The other 71 compounds in the index: 849 matched listings, 24.1% changed price, median change zero. The recommended group repriced slightly less than the market it sits in.

\- Emideltide (sold as DSIP) is the one the panel voted down, by a single vote. It repriced at 20.8% - same band. As of August 11, 2026 its median listed price is $5.80 per milligram, higher than any of the five that were recommended.

\- The "TB-500" the panel voted on is the 7-residue fragment, not the full-length thymosin beta-4 this market actually sells. One vendor in the index lists the fragment; 23 list the full-length protein.



Two reasons this is the expected result: a PCAC vote is advisory and FDA has not opened rulemaking, and a 503A rule governs what a pharmacy may compound against a prescription - not research-use material, which is what every price here describes.



This is listed prices, not transaction prices; no coupons or bulk terms applied, and nothing here tests purity or product quality.

Four weeks after the FDA panel vote, the recommended peptides repriced no more than the rest of the market - and no more than the one the panel rejected